進階篩選

Technical category
技術研發單位
  • 共有:筆資料
  • 顯示:
  • 筆商品
    • Virus and Cell Culture Platform for Vaccine Production Technology

      Excellence Research Center FutureTech Virus and Cell Culture Platform for Vaccine Production Technology

      The "Viral Vaccine Cell Production Technology Platform" of this exhibition is based on 1. Host cell and virus match and colonization technology; 2. Cell-expressed virus receptor technology; 3. Blocking antiviral mechanism of host cell; 4. Immortalization technology of host cell; 5. Serum-free suspension cell culture technology to produce high-immunity virus vaccine strains containing intact virus antigens.
    • Influenza mucosal vaccine compositionpreparationapplication thereof

      Precision Health Ecosystem FutureTech Influenza mucosal vaccine compositionpreparationapplication thereof

      Provided is an influenza mucosal vaccine compositionpreparationapplication thereof. This composition contains an antigen fusion protein which includes an influenza virus antigena Type IIb heat-labile enterotoxin A subunit. Immunization with the antigen fusion protein induces cellularhumoral immune responses, including systemicmucosal immune responses, against a specific in
    • Analysis of Virus Structure of White Tail Disease for Shrimps

      Smart machinerynovel materials FutureTech Analysis of Virus Structure of White Tail Disease for Shrimps

      With the use of E. coli expression system, capsid protein assembly in vitro, X-ray photoprotein crystallographycryo-electron microscope, the T=3 capsid structure of white tail disease viruses for shrimps has been resolved successfully, such that an entire model for capsid structure of virus could be provideda mechanism for viral assemblyinfection could be understood.
    • RSV VACCINE COMPOSITION COMPRISING HEPATITIS B VIRUS-LIKE PARTICLES AS ADJUVANT

      Bio-tech & New Drugs FutureTech RSV VACCINE COMPOSITION COMPRISING HEPATITIS B VIRUS-LIKE PARTICLES AS ADJUVANT

      In this project, we have reorganized several highly immunogenic sitesstructurally essential regions to maintain it in a pre-fusion stateuse it as main antigen in our RSV vaccine candidate (RSV-F005). To induce a mucosal immune response, intranasal administration route was chosen. New mucosal adjuvant (H-muad) has been tested in threee animal models.
本網站使用您的Cookie於優化網站。繼續瀏覽網站即表示您同意本公司隱私權政策,您可至隱私權政策了解詳細資訊。